Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria~* 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening~* inadequate response to a ≥1 month treatment with topical medications~* Atopic dermatitis covering ≥10% of the body surface area~* EASI score ≥16~* Validated Investigator Global Assessment (VIGA) ≥3~* Use of emollient(s) at least 2x daily for 1 week prior to baseline~* Negative coronavirus disease (COVID)-19 results at screening~Exclusion Criteria:~* Uncontrolled moderate-to-severe asthma~* Uncontrolled diabetes~* Stage III or IV cardiac failure~* Severe renal condition~* Major surgery within 8 weeks of screening~* Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline~* Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline~* Received live or live-attenuated vaccine within 4 weeks of baseline~* Prior receipt of RPT193

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPT193 400 mg (Type: EXPERIMENTAL): RPT193 400 mg oral tablet administered daily for 16 weeks
- RPT193 200 mg (Type: EXPERIMENTAL): RPT193 200 mg oral tablet administered daily for 16 weeks
- RPT193 50 mg (Type: EXPERIMENTAL): RPT193 50 mg oral tablet administered daily for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo oral tablet administered daily for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).